@article{a61bbac5909b496aa5deab7a89294028,
title = "CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group",
abstract = "The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extended follow-up was needed to establish long-term effects.",
keywords = "Adolescent, Adult, Age Factors, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Australia, Canada, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Europe, Humans, Israel, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse, Middle Aged, Neoplasm Staging, Prednisone, Proportional Hazards Models, Radiotherapy, Adjuvant, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Vincristine, Young Adult",
author = "Michael Pfreundschuh and Evelyn Kuhnt and Lorenz Tr{\"u}mper and Anders Osterborg and Marek Trneny and Lois Shepherd and Gill, {Devinder S} and Jan Walewski and Ruth Pettengell and Ulrich Jaeger and Pier-Luigi Zinzani and Ofer Shpilberg and Stein Kvaloy and {de Nully Brown}, Peter and Rolf Stahel and Noel Milpied and Armando L{\'o}pez-Guillermo and Viola Poeschel and Sandra Grass and Markus Loeffler and Niels Murawski and {MabThera International Trial (MInT) Group}",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
doi = "10.1016/S1470-2045(11)70235-2",
language = "English",
volume = "12",
pages = "1013--22",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "The/Lancet Publishing Group",
number = "11",
}